Posterior ischemic optic neuropathy (PION) secondary to acute orbital hemorrhage: a case report and literature review.

Arch Soc Esp Oftalmol (Engl Ed)Jul 20, 2026 (epub)
Case ReportOphthalmologyPlastic Surgery

M C Baserga, M Biga, G Morocho Hermosa et al.

✦ AI-curated · Sources linked

Case in brief

A 49-year-old male developed posterior ischemic optic neuropathy (PION) following acute orbital hemorrhage after cosmetic blepharoplasty. He presented with sudden visual loss, painful proptosis, and a relative afferent pupillary defect six hours post-surgery. Despite urgent decompressive surgery, the patient did not regain vision, and optic atrophy was observed one month later, confirming PION.

Diagnostic / clinical pearl

Clinicians should consider posterior ischemic optic neuropathy as a potential cause of acute visual loss following eyelid surgeries, particularly in the context of orbital hemorrhage.

Why it matters

Understanding the mechanisms leading to PION can aid in early recognition and management of visual loss after cosmetic procedures, emphasizing the need for vigilance in postoperative care.

Source

PubMed · PMID 42476409

Published in Arch Soc Esp Oftalmol (Engl Ed). This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Ophthalmology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.